Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline In The Class
Action Lawsuit Against Delcath Systems, Inc.
LOS ANGELES -- June 22, 2013
Glancy Binkow & Goldberg LLP announces that all purchasers of the securities
of Delcath Systems, Inc. (“Delcath” or the “Company”) (NASDAQ:DCTH) between
April 21, 2010 and May 2, 2013 (the “Class Period’) have until July 8, 2013 to
file a motion to be appointed as lead plaintiff in the shareholder lawsuit
filed in the United States District Court for the Southern District of New
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888)
773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER OR IF YOU
PURCHASED DELCATH SHARES PRIOR TO THE CLASS PERIOD. IF YOU INQUIRE BY EMAIL
PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES
Delcath operates as a specialty pharmaceutical and medical device company
focusing on the field of oncology. The Complaint alleges that throughout the
Class Period defendants misrepresented or failed to disclose material adverse
facts about, among other things, the Company's New Drug Application seeking
Food and Drug Administration (FDA) approval for commercial sale of Melblez Kit
-- Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery
System -- for the treatment of patients with unresectable ocular melanoma
metastatic to the liver, including substantial and severe toxicity, and deaths
associated with the drug’s adverse reactions.
To learn more about this action or if you purchased Delcath securities prior
to the Class Period and have any questions concerning this Notice or your
rights or interests with respect to these matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East,
Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or
contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to
firstname.lastname@example.org, or visit our website at http://www.glancylaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 888-773-9224
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, 212-682-5340
Press spacebar to pause and continue. Press esc to stop.